Stay updated on Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed eligibility criteria for a clinical trial on Alveolar Soft Part Sarcoma and the addition of collaborators, specifically Merck Sharp & Dohme LLC and Pfizer. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference45%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.